Acetyl hexapeptide-38 peptide (PAW-β) is a synthetic high-activity cosmetic polypeptide composed of six amino acids modified via acetylation. Featuring targeted delivery, mild potency and superior safety, it stands as an innovative functional raw material widely adopted in medical aesthetics and anti-aging skincare. Unlike traditional volumizing ingredients that work through physical plumping, this peptide exerts effects by regulating biological signaling pathways. It delivers zero foreign-body sensation and minimal irritation, suitable for all skin types including sensitive complexions. Its core skincare benefit lies in adipogenesis and soft tissue volumization, which specifically alleviates aging concerns such as loss of subcutaneous facial fat, facial hollowness, skin atrophy and sagging. It also delivers auxiliary soothing and anti-wrinkle effects.
Our Products Form
Acetyl Hexapeptide-38 COA
Mechanism of Action
Core Function: Targeted Promotion of Adipogenesis for Soft Tissue Volumization
At the root of skin aging lies atrophy of subcutaneous fat pads, accompanied by fewer and less active adipocytes, which results in sunken cheeks, deflated facial contours and weakened skin support. Conventional skincare ingredients primarily focus on collagen repair within the epidermis and dermis, failing to address adipose layer aging. The exclusive core strength of acetyl hexapeptide-38 peptide is its ability to stimulate adipogenesis and precisely plump soft tissues.As a specific biological signaling molecule, this peptide penetrates the epidermis and superficial dermis to reach subcutaneous adipose tissue, where it targets preadipocytes and triggers physiological adipogenic programs.
Distinct from hyaluronic acid that plumps skin via physical water absorption and swelling, its volumizing effect originates from endogenous adipocyte proliferation and lipid accumulation, yielding natural, long-lasting results that align with native skin condition.In terms of functional specificity, PAW-β selectively stimulates benign proliferation of superficial subcutaneous fat on the face and neck without inducing systemic fat gain.
It accurately repairs localized fat deficits to rebuild full, firm facial contours, thickens the subcutaneous adipose layer to reinforce the skin barrier, and boosts skin softness and elasticity. It fundamentally mitigates multiple aging signs including hollowness, sagging and fine lines.
Core Regulatory Pathway: PGC-1α/PPARγ/C/EBPα Adipogenic Differentiation Pathway
The molecular foundation through which PAW-β drives adipogenesis and volumization is its precise activation and modulation of the three-tiered linked PGC-1α/PPARγ/C/EBPα adipogenic differentiation signaling pathway.This pathway serves as the central regulatory cascade governing preadipocyte proliferation, differentiation and lipid synthesis and storage, determining adipocyte maturation efficiency and adipose tissue volume.The pathway operates in a progressive, synergistically activated hierarchical logic.As an upstream activator, PAW-β sequentially regulates the expression of core proteins and genes to fully initiate the complete physiological adipogenic cascade.
Its mode of action unfolds across three tightly linked, mutually reinforcing tiers that collaboratively restore soft tissue volume through physiological fat replenishment.
Tier 1: Upstream Activation and Regulation of PGC-1α – Primary Target
PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1α) is a pivotal upstream transcriptional coactivator governing fat metabolism and adipocyte differentiation, presiding over cellular energy metabolism and the initiation of adipogenesis. Under natural aging conditions, cutaneous PGC-1α expression continuously declines, directly arresting preadipocyte differentiation and impairing lipid synthesis capacity.Laboratory data verifies that PAW-β specifically binds to receptors on preadipocyte membranes to trigger intracellular signal transduction, markedly elevating mRNA and protein expression of PGC-1α.
At a concentration of 0.5 mg/mL, PGC-1α expression rises by 61.1%, fully unlocking upstream adipogenic initiation signals to reverse age-related adipogenic stagnation and lay groundwork for subsequent adipocyte maturation and lipid deposition.Additionally, the ingredient selectively blocks interference from fat-suppressive pathways such as Wnt/β-catenin, stabilizing PGC-1α activation signals and preventing premature termination of adipogenic differentiation.
Tier 2: Core Mediation and Regulation via PPARγ – Critical Hub for Directed Adipocyte Differentiation
Once activated, PGC-1α selectively binds to and activates downstream master transcription factor PPARγ (Peroxisome Proliferator-Activated Receptor Gamma).
As the central governing gene of adipogenic differentiation, PPARγ dictates whether preadipocytes undergo directed maturation into functional adipocytes, functioning as an indispensable mediator of adipogenesis.Upon modulation by acetyl hexapeptide-38 peptide, activated PGC-1α forms a stable transcriptional activation complex with PPARγ, drastically amplifying PPARγ transcriptional activity. This prompts dormant preadipocytes to exit quiescence and launch directed differentiation programs, suppresses cellular apoptosis and fibrosis, and preserves proliferative vitality of adipocytes.This mechanism fundamentally differs from ordinary moisturizing and anti-aging actives by regenerating and repairing adipose tissue at the cellular differentiation level rather than delivering superficial temporary improvement, forming the cornerstone of long-term volumization.
In vitro cellular assays demonstrate that treatment with PAW-β boosts PPARγ transcriptional activity in human preadipocytes by over 50%, significantly elevating directed adipogenic differentiation rates. Differentiated cells retain normal lipid storage capacity with zero risk of abnormal proliferation, confirming exceptional safety profiles.
Tier 3: Terminal Execution Regulation via C/EBPα – Completion of Lipid Accumulation and Volumization
C/EBPα (CCAAT/Enhancer-Binding Protein Alpha) is a key downstream target gene of PPARγ and the terminal regulatory factor governing adipocyte maturation and lipid synthesis. It primarily controls intracellular fatty acid synthesis, triglyceride deposition and adipocyte morphological maturation, directly dictating incremental adipose tissue volume.
PPARγ activation further powerfully induces high expression of the C/EBPα gene, doubly reinforcing pathway activity to drive continuous lipid synthesis and storage in differentiated adipocytes.
Complete lipid droplet formation enlarges adipocyte size and steadily increases cell count, ultimately triggering physiological thickening and volumization of subcutaneous adipose tissue.Furthermore, sustained high C/EBPα expression stabilizes the structure and function of mature adipocytes, extends cellular survival cycles and reduces fat loss for longer-lasting volumizing effects.Experimental data shows that PAW-β treatment elevates intracellular lipid accumulation in adipocytes by up to 32.4%. A 14-day human facial trial records an 11.9% increase in localized volume, and consistent long-term application sustains plump, full skin.
The full PGC-1α/PPARγ/C/EBPα pathway constitutes a closed-loop regulatory system: upstream initiation, midstream mediation and terminal execution. By precisely activating this three-tiered cascade, PAW-β orchestrates the full spectrum of adipocyte differentiation, lipid synthesis and tissue volumization. It resolves subcutaneous fat loss and facial hollowness at the cellular and molecular level to deliver natural, safe, long-lasting volumizing anti-aging benefits – its core technological advantage over competing polypeptides.Notably, this regulatory process fully aligns with human physiological metabolic mechanisms. It requires no exogenous filler injection or hormonal intervention, eliminating adverse reactions including abnormal fat hyperplasia, skin redness and allergic inflammation, making it suitable for long-term anti-aging skincare regimens.
Efficacy on Barrier Repair for Sensitive Skin
Acetyl hexapeptide-38 peptide is suitable for sensitive skin conditions featuring fragility, flushing and compromised skin barriers, with supplementary mild anti-inflammatory and soothing bioactivities. This polypeptide suppresses the release of pro-inflammatory mediators IL-6 and TNF-α in the stratum corneum, mitigates stress responses including burning, stinging and redness triggered by external irritants, and alleviates skin intolerance induced by seasonal transitions or irritating skincare products in sensitive skin.
Modified by acetylation, it boasts a moderate molecular weight with gentle skin penetration.It avoids over-penetration through the stratum corneum that would irritate dermal nerve endings, carrying zero risks of stinging or sensitization. No cases of contact allergy were observed in human clinical patch tests.
Beyond anti-inflammation and soothing effects, the ingredient thickens subcutaneous fat pads by boosting adipocyte differentiation to reinforce the skin's supportive barrier from deep layers. Abundant subcutaneous fat cushions epidermal damage caused by external stressors such as temperature fluctuations, friction and UV radiation, lowering barrier impairment and transepidermal water loss (TEWL).
Meanwhile, mature adipocytes secrete lipid-active substances to facilitate lipid synthesis within the stratum corneum, fill intercellular gaps between keratinocytes, slow cutaneous water loss, and relieve common sensitive skin symptoms such as dryness, peeling and pruritus.
Its regulatory mechanism relies entirely on endogenous physiological cellular modulation without hormones or irritating volumizing agents. Long-term application gradually improves skin tolerance of sensitive complexions, delivering dual benefits of soothing barrier repair and soft tissue volumization.
Discovery History
It is a core raw material for structural anti-aging within the cosmetic polypeptide sector, specially developed by the R&D team of Lipotec, Spain. Conventional cosmetic polypeptides mainly act on the epidermis and dermis, only alleviating superficial skin concerns such as wrinkles and dullness, yet failing to repair deep aging issues including facial hollowness and soft tissue sagging induced by subcutaneous fat atrophy.
To fill this technical gap, the research team adopted high-throughput molecular screening and cellular pathway validation technologies to selectively screen bioactive polypeptide sequences capable of regulating adipogenesis. After iterative optimization, highly active PAW-β was obtained, and its core function of specifically activating the PGC-1α/PPARγ/C/EBPα adipogenic differentiation pathway was verified.
This ingredient completed a full set of safety and efficacy tests and was officially launched onto the market in 2010, marking the first skincare polypeptide featuring physiological fat volumization. Starting from 2018, localized synthesis and large-scale application of this ingredient have been gradually realized in China, and it has been widely incorporated into high-end anti-aging skincare formulations.
References
- BenchChem Technical Support Team. An In-depth Technical Guide to Acetyl Hexapeptide-38 and its Role in Adipocyte Differentiation Pathways[R]. BenchChem, 2026.
- Suzhou Ruijia Biotechnology Co., Ltd. Technical Manual of Acetyl Hexapeptide-38[EB/OL]. 2026.
- ChemicalBook. Database of Efficacy and Physicochemical Properties of Acetyl Hexapeptide-38 (CAS No. 1400634-44-7)[DB/OL]. 2026.
- Cosmetic Ingredients Guide. Acetyl Hexapeptide-38 Efficacy and Mechanism Research[EB/OL]. 2026.
- Hangzhou Chuangpeptide Biotechnology Co., Ltd. Review on R&D History and Applications of Cosmetic Polypeptide Acetyl Hexapeptide-38[EB/OL]. 2024.
Hot Tags: acetyl hexapeptide-38 peptide, China acetyl hexapeptide-38 peptide manufacturers, suppliers
